drugset / Trial / NCT00577850
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
RandomizedParallel-groupOpen-label
Summary
The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.
Timeline
- Start
- 2002-11
- Primary completion
- 2004-02
- Completion
- 2004-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alendronic Acid | Small molecule | 70 mg | Intravenous |
| Subject | Risedronate | Small molecule | 35 mg | Intravenous |